The global anti-infectives market size reached USD 138.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 180.0 Billion by 2033, exhibiting a growth rate (CAGR) of 2.93% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 138.8 Billion |
Market Forecast in 2033
|
USD 180.0 Billion |
Market Growth Rate 2025-2033 | 2.93% |
Anti-infectives are medicines that act against infections, either by inhibiting the spread or killing the infectious agent outright. These medicines include antibiotics, antivirals, antifungals, antimalarials, anthelmintics, and antiprotozoals. They are generally administered through oral, parenteral, and topical routes. They are widely used to treat minor infectious diseases, including pneumonia and tuberculosis. Apart from this, anti-infectives are also utilized during routine procedures and surgeries, such as cesarian section and joint replacement, which are associated with a high risk of severe infection.
The global anti-infectives market is primarily driven by rising incidences of infectious diseases across the globe. Anti-Infinitives are used to treat infections, including viruses, bacteria, parasites, and fungi. Additionally, the development of novel drugs that are formulated using different strategies, such as natural products, quorum sensing inhibitors, biofilm disruptors, gallium-based drugs, cyclodextrin inhibitors, and light-based antimicrobials, are providing an impetus to the market growth. In line with this, the latest innovations in drug discovery procedures, such as stem cells and organ-on-chip (OOC) technologies, to enhance drug trial processes are creating a positive outlook for the market. Furthermore, the increasing product adoption due to the advent of the COVID-19 disease and induced infections, such as aspergillosis, invasive candidiasis, and mucormycosis, is strengthening the growth of the market. Besides this, the increasing number of new anti-infective drugs being approved by the regulatory authorities is acting as another growth-inducing factor. Moreover, the implementation of favorable government policies, rising investments in developing new and innovative drugs, increasing awareness among individuals about infectious diseases, and rapidly improving healthcare infrastructure are anticipated to impel the growth of the market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-infectives market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on type, route of administration and distribution channel.
Breakup by Type:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Cipla Health Ltd. (Cipla Limited), F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Lupin Limited, Sandoz AG (Novartis AG) and Sun Pharmaceutical Industries Limited.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Type, Route of Administration, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Cipla Health Ltd. (Cipla Limited), F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Lupin Limited, Sandoz AG (Novartis AG), Sun Pharmaceutical Industries Limited |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global anti-infectives market was valued at USD 138.8 Billion in 2024.
We expect the global anti-infectives market to exhibit a CAGR of 2.93% during 2025-2033.
The rising incidences of infectious diseases, along with the growing adoption of anti-infectives during routine procedures and surgeries, such as cesarian section and joint replacement, which are associated with a high risk of severe infection, are primarily driving the global anti-infectives market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing utilization of anti-infectives to treat infections, including viruses, bacteria, parasites, and fungi to combat the spread of the coronavirus infection upon human intervention.
Based on the type, the global anti-infectives market can be segmented into antibacterial, antifungal, and antiviral. Currently, antiviral holds the majority of the total market share.
Based on the route of administration, the global anti-infectives market has been divided into topical, oral, Intravenous (IV), and others. Among these, oral currently exhibits a clear dominance in the market.
Based on the distribution channel, the global anti-infectives market can be categorized into hospital pharmacies, retail pharmacies, speciality pharmacies, online stores, and others. Currently, hospital pharmacies account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global anti-infectives market include Abbott Laboratories, Cipla Health Ltd. (Cipla Limited), F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Lupin Limited, Sandoz AG (Novartis AG), and Sun Pharmaceutical Industries Limited.